Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Current Assets (2017 - 2021)

Cogent Biosciences has reported Current Assets over the past 5 years, most recently at $207.5 million for Q3 2021.

  • Quarterly results put Current Assets at $207.5 million for Q3 2021, up 55.53% from a year ago — trailing twelve months through Sep 2021 was $207.5 million (up 55.53% YoY), and the annual figure for FY2020 was $244.9 million, up 503.37%.
  • Current Assets for Q3 2021 was $207.5 million at Cogent Biosciences, down from $221.4 million in the prior quarter.
  • Over the last five years, Current Assets for COGT hit a ceiling of $244.9 million in Q4 2020 and a floor of $23.9 million in Q2 2020.
  • Median Current Assets over the past 5 years was $75.5 million (2018), compared with a mean of $103.5 million.
  • Biggest five-year swings in Current Assets: crashed 59.13% in 2020 and later soared 824.26% in 2021.
  • Cogent Biosciences' Current Assets stood at $42.4 million in 2017, then surged by 91.14% to $81.0 million in 2018, then crashed by 49.89% to $40.6 million in 2019, then surged by 503.37% to $244.9 million in 2020, then decreased by 15.27% to $207.5 million in 2021.
  • The last three reported values for Current Assets were $207.5 million (Q3 2021), $221.4 million (Q2 2021), and $232.1 million (Q1 2021) per Business Quant data.